- 産業: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells. This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen.
Industry:Pharmaceutical
A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). Gavilimomab recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, gavilimomab does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD.
Industry:Pharmaceutical
A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells. Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity.
Industry:Pharmaceutical
A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells. When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues. This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils.
Industry:Pharmaceutical
A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.
Industry:Pharmaceutical
A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2. 3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth.
Industry:Pharmaceutical
A multivalent vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis.
Industry:Pharmaceutical
A murine IgG1 anti-CD45 monoclonal antibody (MoAb) with immunotherapeutic activity. CD45 antigen, a receptor protein-tyrosine phosphatase essential for T cell development and lymphocyte activation, is expressed on virtually all leukocytes. MoAb BC8 has specificity for hematopoietic tissues and may be used in targeted immunotherapy.
Industry:Pharmaceutical
A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27. 15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth.
Industry:Pharmaceutical
A multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration, polyvalent antigen-KLH conjugate vaccine may induce production of IgG and IgM antibodies and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these TAAs, resulting in tumor cell death and tumor growth inhibition. Globo H (globo H hexasaccharide 1); GM2 ganglioside; Tn-MUC1 (human tumor-associated epithelial mucin 1 carrying the tumor-specific glycan Tn); TF (Thompson-Friedreich); and sTn (sialyl-Tn) are overexpressed in a variety of cancer cells. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition of antigens.
Industry:Pharmaceutical
